## **Core Concept**
Chronic myeloid leukemia (CML) is a type of cancer that affects the white blood cells and tends to progress slowly over time. It is characterized by the clonal expansion of a transformed hematopoietic stem cell. A hallmark genetic abnormality in CML is the **Philadelphia chromosome**, which results from a reciprocal translocation between chromosomes 9 and 22.

## **Why the Correct Answer is Right**
The correct answer, , is associated with the Philadelphia chromosome, which is a result of the t(9;22) chromosomal translocation. This translocation creates a fusion gene, **BCR-ABL**, which encodes a constitutively active tyrosine kinase. The BCR-ABL fusion protein leads to uncontrolled proliferation of myeloid cells in the bone marrow, peripheral blood, and sometimes in other organs. The presence of the Philadelphia chromosome or the BCR-ABL fusion gene is a diagnostic hallmark of CML.

## **Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because while leukocytosis (an increase in the number of white blood cells) can be seen in CML, it is not specific to CML and can occur in various other conditions.
* **Option B:** This option might refer to another genetic abnormality or finding not specifically characteristic of CML.
* **Option D:** This option might represent another condition or finding not directly related to the diagnostic hallmark of CML.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl for CML is that the disease often presents in a **chronic phase**, which can last for years, but may progress to an **accelerated phase** or **blast crisis**, which are more aggressive and harder to treat. The introduction of **tyrosine kinase inhibitors (TKIs)**, such as imatinib, has significantly improved the prognosis for patients with CML by specifically targeting the BCR-ABL tyrosine kinase.

## **Correct Answer:** . Philadelphia chromosome.